Analyst Activity: HollyFrontier Corp (NYSE:HFC)

Analysts are weighing in on how HollyFrontier Corp (NYSE:HFC), might perform in the near term. Wall Street analysts have a much less favorable assessment of the stock, with a mean rating of 2.9. The stock is rated as buy by 4 analysts, with 2 outperform and 10 hold rating. The rating score is on a scale of 1 to 5 where 1 stands for strong buy and 5 stands for strong sell.

For the current quarter, the 17.00 analysts offering adjusted EPS forecast have a consensus estimate of $0.58 a share, which would compare with $1.45 in the same quarter last year. They have a high estimate of $1.29 and a low estimate of $0.30. Revenue for the period is expected to total nearly $2.35B from $3.70B the year-ago period.

For the full year, 12.00 Wall Street analysts forecast this company would deliver earnings of 1.79 per share, with a high estimate of $2.85 and a low estimate of $0.76. It had reported earnings per share of $4.67 in the corresponding quarter of the previous year. Revenue for the period is expected to total nearly $10.15B versus 13.24B in the preceding year.

The analysts project the company to maintain annual growth of around 10.55% percent over the next five years as compared to an average growth rate of 8.52% percent expected for its competitors in the same industry.

Among the 13 analysts Data provided by Thomson/First Call tracks, the 12-month average price target for HFC is $36.46 but some analysts are projecting the price to go as high as $55.00. If the optimistic analysts are correct, that represents a 122 percent upside potential from the recent closing price of $24.80. Some sell-side analysts, particularly the bearish ones, have called for $24.00 price targets on shares of HollyFrontier Corp (NYSE:HFC).

In the last reported results, the company reported earnings of $1.45 per share, while analysts were calling for share earnings of $1.30. It was an earnings surprise of 11.50%percent. In the matter of earnings surprises, the term Cockroach Effect is often implied. Cockroach Effect is a market theory that suggests that when a company reveals bad news to the public, there may be many more related negative events that have yet to be revealed. In the case of earnings surprises, if a company is suggesting a negative earnings surprise it means there are more to come.

HollyFrontier Corporation operates as an independent petroleum refiner in the United States. The company operates in two segments, Refining and HEP. It primarily produces high-value refined products, such as gasoline, diesel fuel, jet fuel, specialty lubricant products, liquid petroleum gas, fuel oil, and specialty and modified asphalt. The company offers its products to other refiners, convenience store chains, independent marketers, retailers, truck stop chains, wholesalers, railroads, governmental entities, paving contractors or manufacturers, and commercial and specialty markets, as well as for commercial airline use. It owns and operates five refineries with a combined crude oil processing capacity of approximately 443,000 barrels per day in El Dorado, Kansas; Tulsa, Oklahoma; Artesia, New Mexico; Cheyenne, Wyoming; Woods Cross, Utah, as well as owns and operates asphalt terminals in Arizona, New Mexico, and Oklahoma; and vacuum distillation and other facilities in Lovington, New Mexico. HollyFrontier Corporations refineries serve markets in the Mid-Continent, Southwest, and Rocky Mountain regions of the United States. The company was formerly known as Holly Corporation and changed its name to HollyFrontier Corporation as a result of its merger with Frontier Oil Corporation in July 2011. HollyFrontier Corporation was founded in 1947 and is based in Dallas, Texas.

Analyst Activity: Juniper Networks, Inc. (NYSE:JNPR)

Analysts are weighing in on how Juniper Networks, Inc. (NYSE:JNPR) , might perform in the near term. Wall Street analysts have a much less favorable assessment of the stock, with a mean rating of 2.7. The stock is rated as buy by 4 analysts, with 3 outperform and 23 hold rating. The rating score is on a scale of 1 to 5 where 1 stands for strong buy and 5 stands for strong sell.

For the current quarter, the 27.00 analysts offering adjusted EPS forecast have a consensus estimate of $0.47 a share, which would compare with $0.53 in the same quarter last year. They have a high estimate of $0.51 and a low estimate of $0.46. Revenue for the period is expected to total nearly $1.19B from $1.22B the year-ago period.

For the full year, 27.00 Wall Street analysts forecast this company would deliver earnings of 2.00 per share, with a high estimate of $2.21 and a low estimate of $1.85. It had reported earnings per share of $2.03 in the corresponding quarter of the previous year. Revenue for the period is expected to total nearly $4.86B versus 4.86B in the preceding year.

The analysts project the company to maintain annual growth of around 12.98% percent over the next five years as compared to an average growth rate of 14.99% percent expected for its competitors in the same industry.

Among the 22 analysts Data provided by Thomson/First Call tracks, the 12-month average price target for JNPR is $26.50 but some analysts are projecting the price to go as high as $36.00. If the optimistic analysts are correct, that represents a 50 percent upside potential from the recent closing price of $24.04. Some sell-side analysts, particularly the bearish ones, have called for $22.90 price targets on shares of Juniper Networks, Inc. (NYSE:JNPR) .

In the last reported results, the company reported earnings of $0.53 per share, while analysts were calling for share earnings of $0.40. It was an earnings surprise of 32.50%percent. In the matter of earnings surprises, the term Cockroach Effect is often implied. Cockroach Effect is a market theory that suggests that when a company reveals bad news to the public, there may be many more related negative events that have yet to be revealed. In the case of earnings surprises, if a company is suggesting a negative earnings surprise it means there are more to come.

Juniper Networks, Inc. designs, develops, and sells network products and services worldwide. It offers various routing products, including ACX series universal access routers to deploy new high-bandwidth services; MX series Ethernet routers that functions as a universal edge platform; M series edge routers; PTX series packet transport routers; T series routers; and NorthStar controllers. The company also provides various switching products comprising EX series Ethernet switches to address the access, aggregation, and core layer switching requirements of micro branch, branch office, and campus and data center environments; QFX series of core, spine, and top-of-rack data center switches; and OCX1100, an open networking switch. In addition, it offers security products, such as SRX series services gateways for the data centers; Branch SRX family that includes SRX300 Series and SRX1500, which provides integrated firewall capabilities; vSRX Virtual Firewall that delivers various features of physical firewalls; Spotlight Secure Threat Intelligence Platform, a threat intelligence platform that aggregates threat feeds from various sources; and Sky Advanced Threat Prevention, a cloud-based service for static and dynamic analysis. Further, the company offers Junos OS, a network operating system; Junos Space, a network management platform for creating network management applications that include network director, services activation director, security director, edge services director, service now, and service insight; and Contrail networking and cloud platform solutions. Additionally, it provides technical support and professional services, as well as education and training programs. The company sells its products through direct sales, distributors, value-added resellers, and original equipment manufacturer partners to end-users in the service provider and enterprise markets. Juniper Networks, Inc. was founded in 1996 and is headquartered in Sunnyvale, California.

Analyst Activity: Las Vegas Sands Corp. (NYSE:LVS)

Analysts are weighing in on how Las Vegas Sands Corp. (NYSE:LVS), might perform in the near term. Wall Street analysts have a much less favorable assessment of the stock, with a mean rating of 2.5. The stock is rated as buy by 6 analysts, with 2 outperform and 11 hold rating. The rating score is on a scale of 1 to 5 where 1 stands for strong buy and 5 stands for strong sell.

For the current quarter, the 16.00 analysts offering adjusted EPS forecast have a consensus estimate of $0.57 a share, which would compare with $0.60 in the same quarter last year. They have a high estimate of $0.59 and a low estimate of $0.50. Revenue for the period is expected to total nearly $2.78B from $2.92B the year-ago period.

For the full year, 18.00 Wall Street analysts forecast this company would deliver earnings of 2.31 per share, with a high estimate of $2.52 and a low estimate of $1.89. It had reported earnings per share of $2.55 in the corresponding quarter of the previous year. Revenue for the period is expected to total nearly $11.43B versus 11.69B in the preceding year.

The analysts project the company to maintain annual growth of around -3.69% percent over the next five years as compared to an average growth rate of 16.50% percent expected for its competitors in the same industry.

Among the 16 analysts Data provided by Thomson/First Call tracks, the 12-month average price target for LVS is $52.50 but some analysts are projecting the price to go as high as $62.00. If the optimistic analysts are correct, that represents a 34 percent upside potential from the recent closing price of $46.16. Some sell-side analysts, particularly the bearish ones, have called for $42.00 price targets on shares of Las Vegas Sands Corp. (NYSE:LVS).

In the last reported results, the company reported earnings of $0.60 per share, while analysts were calling for share earnings of $0.61. It was an earnings surprise of -1.60%percent. In the matter of earnings surprises, the term Cockroach Effect is often implied. Cockroach Effect is a market theory that suggests that when a company reveals bad news to the public, there may be many more related negative events that have yet to be revealed. In the case of earnings surprises, if a company is suggesting a negative earnings surprise it means there are more to come.

Las Vegas Sands Corp., together with its subsidiaries, develops, owns, and operates integrated resorts in Asia and the United States. It owns and operates The Venetian Macao Resort Hotel, Sands Cotai Central, the Four Seasons Hotel Macao, Cotai Strip, the Plaza Casino, and the Sands Macao in Macao, the Peoples Republic of China; and iconic Marina Bay Sands in Singapore. The company also owns and operates The Venetian Resort Hotel Casino, The Palazzo Resort Hotel Casino, and Five-Diamond luxury resorts on the Las Vegas Strip; Sands Expo and Convention Center in Las Vegas, Nevada; and the Sands Casino Resort Bethlehem in Bethlehem, Pennsylvania. Its integrated resorts include accommodations, gaming, entertainment and retail, convention and exhibition facilities, celebrity chef restaurants, and other amenities. Las Vegas Sands Corp. was founded in 1988 and is based in Las Vegas, Nevada.

Analyst Activity: St. Jude Medical Incorporated (NYSE:STJ)

Analysts are weighing in on how St. Jude Medical, Inc. (NYSE:STJ), might perform in the near term. Wall Street analysts have a much less favorable assessment of the stock, with a mean rating of 2.8. The stock is rated as buy by 1 analysts, with 2 outperform and 20 hold rating. The rating score is on a scale of 1 to 5 where 1 stands for strong buy and 5 stands for strong sell.

For the current quarter, the 22.00 analysts offering adjusted EPS forecast have a consensus estimate of $1.06 a share, which would compare with $1.03 in the same quarter last year. They have a high estimate of $1.07 and a low estimate of $1.03. Revenue for the period is expected to total nearly $1.55B from $1.41B the year-ago period.

For the full year, 24.00 Wall Street analysts forecast this company would deliver earnings of 4.06 per share, with a high estimate of $4.11 and a low estimate of $4.00. It had reported earnings per share of $3.94 in the corresponding quarter of the previous year. Revenue for the period is expected to total nearly $6.04B versus 5.54B in the preceding year.

The analysts project the company to maintain annual growth of around 10.61% percent over the next five years as compared to an average growth rate of 12.91% percent expected for its competitors in the same industry.

Among the 20 analysts Data provided by Thomson/First Call tracks, the 12-month average price target for STJ is $72.67 but some analysts are projecting the price to go as high as $89.00. If the optimistic analysts are correct, that represents a 13 percent upside potential from the recent closing price of $78.49. Some sell-side analysts, particularly the bearish ones, have called for $60.00 price targets on shares of St. Jude Medical, Inc. (NYSE:STJ).

In the last reported results, the company reported earnings of $1.03 per share, while analysts were calling for share earnings of $1.00. It was an earnings surprise of 3.00%percent. In the matter of earnings surprises, the term Cockroach Effect is often implied. Cockroach Effect is a market theory that suggests that when a company reveals bad news to the public, there may be many more related negative events that have yet to be revealed. In the case of earnings surprises, if a company is suggesting a negative earnings surprise it means there are more to come.

St. Jude Medical, Inc., together with its subsidiaries, develops, manufactures, and distributes cardiovascular medical devices for cardiac rhythm management, cardiovascular, and atrial fibrillation therapy areas worldwide. It operates in two divisions, Implantable Electronic Systems, and Cardiovascular and Ablation Technologies. The company offers tachycardia implantable cardioverter defibrillator systems and cardiac resynchronization therapy defibrillator devices to treat patients with tachycardia. It also provides atrial fibrillation products comprising electrophysiology, introducers and catheters, advanced cardiac mapping, navigation and recording systems, and ablation systems; and pacemakers, which deliver low-voltage electrical impulses to stimulate a heartbeat for patients whose hearts beat too slowly. In addition, the company offers vascular closure devices, compression assist devices, pressure measurement guidewires, diagnostic coronary imaging technology, percutaneous catheter introducers, diagnostic guidewires, heart failure monitoring devices, renal denervation technology and vascular plugs, optical coherence tomography imaging products, and other vascular accessories, as well as CardioMEMS, a heart failure monitoring device. Further, it provides structural heart products, including heart valve replacement and repair products, and structural heart defect devices; neuromodulation products, such as spinal cord stimulation and radiofrequency ablation to treat chronic pain, as well as deep brain stimulation to treat movement disorders; and thoratec products comprising ventricular assist devices and percutaneous heart pumps. The company sells its products through direct sales force and independent distributors. St. Jude Medical, Inc. was founded in 1976 and is headquartered in St. Paul, Minnesota.

Analyst Activity: Superior Energy Services, Inc. (NYSE:SPN)

Analysts are weighing in on how Superior Energy Services, Inc. (NYSE:SPN), might perform in the near term. Wall Street analysts have a  assessment of the stock, with a mean rating of 2.0. The stock is rated as buy by 10 analysts, with 10 outperform and 10 hold rating. The rating score is on a scale of 1 to 5 where 1 stands for strong buy and 5 stands for strong sell.

For the current quarter, the 28.00 analysts offering adjusted EPS forecast have a consensus estimate of $-0.57 a share, which would compare with $-0.31 in the same quarter last year. They have a high estimate of $-0.47 and a low estimate of $-0.64. Revenue for the period is expected to total nearly $369.33M from $710.78M the year-ago period.

For the full year, 30.00 Wall Street analysts forecast this company would deliver earnings of -2.12 per share, with a high estimate of $-1.63 and a low estimate of $-2.39. It had reported earnings per share of $-1.19 in the corresponding quarter of the previous year. Revenue for the period is expected to total nearly $1.55B versus 2.77B in the preceding year.

The analysts project the company to maintain annual growth of around -69.61% percent over the next five years as compared to an average growth rate of 8.52% percent expected for its competitors in the same industry.

Among the 26 analysts Data provided by Thomson/First Call tracks, the 12-month average price target for SPN is $19.04 but some analysts are projecting the price to go as high as $28.00. If the optimistic analysts are correct, that represents a 44 percent upside potential from the recent closing price of $19.44. Some sell-side analysts, particularly the bearish ones, have called for $13.00 price targets on shares of Superior Energy Services, Inc. (NYSE:SPN).

In the last reported results, the company reported earnings of $-0.31 per share, while analysts were calling for share earnings of $-0.31. It was an earnings surprise of 0.00%percent. In the matter of earnings surprises, the term Cockroach Effect is often implied. Cockroach Effect is a market theory that suggests that when a company reveals bad news to the public, there may be many more related negative events that have yet to be revealed. In the case of earnings surprises, if a company is suggesting a negative earnings surprise it means there are more to come.

Superior Energy Services, Inc. provides specialized oilfield services and equipment to crude oil and natural gas exploration and production companies in the United States, the Gulf of Mexico, and internationally. It operates through four segments: Drilling Products and Services; Onshore Completion and Workover Services; Production Services; and Technical Solutions. The Drilling Products and Services segment rents tubulars, including primary drill pipe strings, tubing landing strings, completion tubulars, and associated accessories; and manufactures and rents bottom hole tools, such as stabilizers, non-magnetic drill collars, and hole openers, as well as rents temporary onshore and offshore accommodation modules and accessories. The Onshore Completion and Workover Services segment offers pressure pumping services comprising hydraulic fracturing and high pressure pumping services used to complete and stimulate production in new oil and gas wells; fluid management services used to obtain, move, store, and dispose of fluids that are involved in the exploration, development, and production of oil and gas reservoirs; and workover services consisting of installations, completions, and sidetracking of wells, as well as support for perforating operations. The Production Services segment provides intervention services, including coiled tubing, cased hole and mechanical wireline, hydraulic workover and snubbing, production testing and optimization, and remedial pumping services. The Technical Solutions segment offers pressure control services; completion tools and services, such as sand control systems, well screens and filters, and surface-controlled sub surface safety valves; and offshore well decommissioning services, including plugging and abandoning wells at the end of their economic life, and dismantling and removing associated infrastructure. Superior Energy Services, Inc. was founded in 1991 and is headquartered in Houston, Texas.

Analyst Review Alert: ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)

Analysts are weighing in on how ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) , might perform in the near term. Wall Street analysts have a much less favorable assessment of the stock, with a mean rating of 2.1. The stock is rated as buy by 7 analysts, with 2 outperform and 1 hold rating. The rating score is on a scale of 1 to 5 where 1 stands for strong buy and 5 stands for strong sell.

For the current quarter, the 9.00 analysts offering adjusted EPS forecast have a consensus estimate of $-0.49 a share, which would compare with $-0.39 in the same quarter last year. They have a high estimate of $-0.41 and a low estimate of $-0.58. Revenue for the period is expected to total nearly $80.00K from $1,000.00 the year-ago period.

For the full year, 9.00 Wall Street analysts forecast this company would deliver earnings of -1.70 per share, with a high estimate of $-0.99 and a low estimate of $-1.95. It had reported earnings per share of $-1.63 in the corresponding quarter of the previous year. Revenue for the period is expected to total nearly $27.86M versus 61.00K in the preceding year.

The analysts project the company to maintain annual growth of around 73.60% percent over the next five years as compared to an average growth rate of 12.91% percent expected for its competitors in the same industry.

Among the 10 analysts Data provided by Thomson/First Call tracks, the 12-month average price target for ACAD is $45.70 but some analysts are projecting the price to go as high as $54.00. If the optimistic analysts are correct, that represents a 61 percent upside potential from the recent closing price of $33.50. Some sell-side analysts, particularly the bearish ones, have called for $35.00 price targets on shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) .

In the last reported results, the company reported earnings of $-0.39 per share, while analysts were calling for share earnings of $-0.33. It was an earnings surprise of -18.20%percent. In the matter of earnings surprises, the term Cockroach Effect is often implied. Cockroach Effect is a market theory that suggests that when a company reveals bad news to the public, there may be many more related negative events that have yet to be revealed. In the case of earnings surprises, if a company is suggesting a negative earnings surprise it means there are more to come.

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. Its lead product candidate, NUPLAZID, has completed the Phase III pivotal trials for the treatment of Parkinsons disease psychosis and the Phase II trial for the treatment of schizophrenia, as well as is in Phase II study for the treatment of Alzheimers disease psychosis. It also has clinical-stage programs for glaucoma and, in collaboration with Allergan, Inc., for chronic pain. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.

Analyst Review Alert: Allergan plc Ordinary Shares (NYSE:AGN)

Analysts are weighing in on how Allergan plc Ordinary Shares (NYSE:AGN), might perform in the near term. Wall Street analysts have a much favorable assessment of the stock, with a mean rating of 1.9. The stock is rated as buy by 10 analysts, with 6 outperform and 4 hold rating. The rating score is on a scale of 1 to 5 where 1 stands for strong buy and 5 stands for strong sell.

For the current quarter, the 14.00 analysts offering adjusted EPS forecast have a consensus estimate of $3.38 a share, which would compare with $4.41 in the same quarter last year. They have a high estimate of $3.67 and a low estimate of $3.10. Revenue for the period is expected to total nearly $4.11B from $5.73B the year-ago period.

For the full year, 17.00 Wall Street analysts forecast this company would deliver earnings of 14.23 per share, with a high estimate of $14.78 and a low estimate of $13.70. It had reported earnings per share of $13.43 in the corresponding quarter of the previous year. Revenue for the period is expected to total nearly $16.76B versus 15.07B in the preceding year.

The analysts project the company to maintain annual growth of around 11.85% percent over the next five years as compared to an average growth rate of 16.51% percent expected for its competitors in the same industry.

Among the 16 analysts Data provided by Thomson/First Call tracks, the 12-month average price target for AGN is $292.63 but some analysts are projecting the price to go as high as $400.00. If the optimistic analysts are correct, that represents a 71 percent upside potential from the recent closing price of $233.51. Some sell-side analysts, particularly the bearish ones, have called for $232.00 price targets on shares of Allergan plc Ordinary Shares (NYSE:AGN).

In the last reported results, the company reported earnings of $4.41 per share, while analysts were calling for share earnings of $4.38. It was an earnings surprise of 0.70%percent. In the matter of earnings surprises, the term Cockroach Effect is often implied. Cockroach Effect is a market theory that suggests that when a company reveals bad news to the public, there may be many more related negative events that have yet to be revealed. In the case of earnings surprises, if a company is suggesting a negative earnings surprise it means there are more to come.

Allergan plc, a specialty pharmaceutical company, develops, manufactures, markets, and distributes medical aesthetics, biosimilar, and over-the-counter pharmaceutical products worldwide. It operates through US Brands, US Medical Aesthetics, International Brands, and Anda Distribution segments. The company offers a portfolio of products that provide treatments for the central nervous system, gastroenterology, womens health and urology, ophthalmology, neurosciences, and medical aesthetics, as well as dermatology and plastic surgery. It is also involved in developing ocular implants that reduce intraocular pressure associated with glaucoma; medical devices for the correction of prominent ears; and intranasal neurostimulation devices, as well as other dry eye products. Allergan plc also distributes generic and branded pharmaceutical products primarily to independent pharmacies, pharmacy chains, pharmacy buying groups, and physicians offices. The company was formerly known as Actavis plc and changed its name to Allergan plc in June 2015. Allergan plc was founded in 1983 and is headquartered in Parsippany, New Jersey.

Analyst Review Alert: Apache Corporation (NYSE:APA)

Analysts are weighing in on how Apache Corporation (NYSE:APA), might perform in the near term. Wall Street analysts have a much less favorable assessment of the stock, with a mean rating of 2.8. The stock is rated as buy by 7 analysts, with 4 outperform and 18 hold rating. The rating score is on a scale of 1 to 5 where 1 stands for strong buy and 5 stands for strong sell.

For the current quarter, the 26.00 analysts offering adjusted EPS forecast have a consensus estimate of $-0.39 a share, which would compare with $0.22 in the same quarter last year. They have a high estimate of $0.04 and a low estimate of $-1.25. Revenue for the period is expected to total nearly $1.23B from $1.98B the year-ago period.

For the full year, 28.00 Wall Street analysts forecast this company would deliver earnings of -1.07 per share, with a high estimate of $0.05 and a low estimate of $-3.45. It had reported earnings per share of $-0.34 in the corresponding quarter of the previous year. Revenue for the period is expected to total nearly $5.09B versus 6.37B in the preceding year.

The analysts project the company to maintain annual growth of around -43.84% percent over the next five years as compared to an average growth rate of 8.52% percent expected for its competitors in the same industry.

Among the 31 analysts Data provided by Thomson/First Call tracks, the 12-month average price target for APA is $56.23 but some analysts are projecting the price to go as high as $67.00. If the optimistic analysts are correct, that represents a 15 percent upside potential from the recent closing price of $58.16. Some sell-side analysts, particularly the bearish ones, have called for $40.00 price targets on shares of Apache Corporation (NYSE:APA).

In the last reported results, the company reported earnings of $0.22 per share, while analysts were calling for share earnings of $-0.26. It was an earnings surprise of 184.60%percent. In the matter of earnings surprises, the term Cockroach Effect is often implied. Cockroach Effect is a market theory that suggests that when a company reveals bad news to the public, there may be many more related negative events that have yet to be revealed. In the case of earnings surprises, if a company is suggesting a negative earnings surprise it means there are more to come.

Apache Corporation, an independent energy company, explores, develops, and produces natural gas, crude oil, and natural gas liquids. It operates onshore and offshore assets primarily in the Permian Basin, the Anadarko basin in western Oklahoma, the Texas Panhandle, and Gulf Coast areas of the United States, as well as in Western Canada and Gulf of Mexico. The company also operates assets in Egypt and the United Kingdom in the North Sea. As of December 31, 2015, it had total estimated proved reserves of 794 million barrels of crude oil, 198 million barrels of natural gas liquids, and 3.4 trillion cubic feet of natural gas. Apache Corporation was founded in 1954 and is based in Houston, Texas.

Analyst Review Alert: Boeing Co (NYSE:BA)

Analysts are weighing in on how Boeing Co (NYSE:BA), might perform in the near term. Wall Street analysts have a much less favorable assessment of the stock, with a mean rating of 2.4. The stock is rated as buy by 5 analysts, with 4 outperform and 9 hold rating. The rating score is on a scale of 1 to 5 where 1 stands for strong buy and 5 stands for strong sell.

For the current quarter, the 16.00 analysts offering adjusted EPS forecast have a consensus estimate of $2.15 a share, which would compare with $1.62 in the same quarter last year. They have a high estimate of $2.28 and a low estimate of $1.96. Revenue for the period is expected to total nearly $23.22B from $24.54B the year-ago period.

For the full year, 20.00 Wall Street analysts forecast this company would deliver earnings of 8.49 per share, with a high estimate of $8.82 and a low estimate of $8.27. It had reported earnings per share of $7.72 in the corresponding quarter of the previous year. Revenue for the period is expected to total nearly $93.81B versus 96.11B in the preceding year.

The analysts project the company to maintain annual growth of around 10.45% percent over the next five years as compared to an average growth rate of 9.86% percent expected for its competitors in the same industry.

Among the 18 analysts Data provided by Thomson/First Call tracks, the 12-month average price target for BA is $148.33 but some analysts are projecting the price to go as high as $196.00. If the optimistic analysts are correct, that represents a 47 percent upside potential from the recent closing price of $133.55. Some sell-side analysts, particularly the bearish ones, have called for $101.00 price targets on shares of Boeing Co (NYSE:BA).

In the last reported results, the company reported earnings of $1.62 per share, while analysts were calling for share earnings of $1.37. It was an earnings surprise of 18.20%percent. In the matter of earnings surprises, the term Cockroach Effect is often implied. Cockroach Effect is a market theory that suggests that when a company reveals bad news to the public, there may be many more related negative events that have yet to be revealed. In the case of earnings surprises, if a company is suggesting a negative earnings surprise it means there are more to come.

The Boeing Company, together with its subsidiaries, designs, develops, manufactures, sells, services, and supports commercial jetliners, military aircraft, satellites, missile defense, human space flight, and launch systems and services worldwide. The company operates in five segments: Commercial Airplanes, Boeing Military Aircraft, Network & Space Systems, Global Services & Support, and Boeing Capital. The Commercial Airplanes segment develops, produces, and markets commercial jet aircraft for various passenger and cargo requirements, as well as provides related support services to the commercial airline industry. This segment also offers aviation services support, aircraft modifications, spare parts, training, maintenance documents, and technical advice to commercial and government customers. The Boeing Military Aircraft segment is involved in the research, development, production, and modification of manned and unmanned military aircraft and weapons systems for the global strike, vertical lift, and autonomous systems, as well as mobility, surveillance, and engagement. The Network & Space Systems segment engages in the research, development, production, and modification of electronics and information solutions; strategic missile and defense systems; space and intelligence systems; and space exploration products. The Global Services and Support segment offers integrated logistics, including supply chain management and engineering support; maintenance, modification, and upgrades for aircraft; and training systems and government services, such as pilot and maintenance training. The Boeing Capital segment facilitates, arranges, structures, and provides financing solutions, such as equipment under operating leases, finance leases, notes and other receivables, assets held for sale or re-lease, and investments. The Boeing Company was founded in 1916 and is based in Chicago, Illinois.

Analyst Review Alert: CenterPoint Energy, Inc. (NYSE:CNP)

Analysts are weighing in on how CenterPoint Energy, Inc. (NYSE:CNP), might perform in the near term. Wall Street analysts have a much less favorable assessment of the stock, with a mean rating of 2.6. The stock is rated as buy by 2 analysts, with 3 outperform and 9 hold rating. The rating score is on a scale of 1 to 5 where 1 stands for strong buy and 5 stands for strong sell.

For the current quarter, the 6.00 analysts offering adjusted EPS forecast have a consensus estimate of $0.19 a share, which would compare with $0.19 in the same quarter last year. They have a high estimate of $0.23 and a low estimate of $0.12. Revenue for the period is expected to total nearly $1.62B from $1.53B the year-ago period.

For the full year, 14.00 Wall Street analysts forecast this company would deliver earnings of 1.14 per share, with a high estimate of $1.17 and a low estimate of $1.03. It had reported earnings per share of $1.10 in the corresponding quarter of the previous year. Revenue for the period is expected to total nearly $7.75B versus 7.39B in the preceding year.

The analysts project the company to maintain annual growth of around 5.60% percent over the next five years as compared to an average growth rate of 6.59% percent expected for its competitors in the same industry.

Among the 12 analysts Data provided by Thomson/First Call tracks, the 12-month average price target for CNP is $22.54 but some analysts are projecting the price to go as high as $26.00. If the optimistic analysts are correct, that represents a 11 percent upside potential from the recent closing price of $23.49. Some sell-side analysts, particularly the bearish ones, have called for $19.00 price targets on shares of CenterPoint Energy, Inc. (NYSE:CNP).

In the last reported results, the company reported earnings of $0.19 per share, while analysts were calling for share earnings of $0.19. It was an earnings surprise of 0.00%percent. In the matter of earnings surprises, the term Cockroach Effect is often implied. Cockroach Effect is a market theory that suggests that when a company reveals bad news to the public, there may be many more related negative events that have yet to be revealed. In the case of earnings surprises, if a company is suggesting a negative earnings surprise it means there are more to come.

CenterPoint Energy, Inc. operates as a public utility holding company in the United States. The companys Electric Transmission & Distribution segment offers electric transmission and distribution services to retail electric providers, municipalities, electric cooperatives, and other distribution companies. As of December 31, 2015, this segment owned 28,474 pole miles of overhead distribution lines and 3,723 circuit miles of overhead transmission lines; 23,120 circuit miles of underground distribution lines and 26 circuit miles of underground transmission lines; and 232 substations with a capacity of 58,674 megavolt amperes. Its Natural Gas Distribution segment sells regulated intrastate natural gas; provides natural gas transportation and storage services for residential, commercial, industrial, and transportation customers; and offers unregulated services comprising residential appliance repair and maintenance services, as well as sells heating, ventilating and air conditioning equipment. This segment owned approximately 74,000 linear miles of natural gas distribution mains. The companys Energy Services segment provides physical natural gas supplies primarily to commercial and industrial customers, and electric and gas utilities; natural gas management services; and physical delivery services, as well as procures and optimizes transportation and storage assets. It owns and operates approximately 200 miles of intrastate pipelines; and leases transportation capacity on various interstate and intrastate pipelines, and storage. Its Midstream Investments segment provides gathering, processing, compression, treating, dehydration, and natural gas liquids fractionation for producer customers. This segment had approximately 12,400 miles of gathering pipelines, 7,900 miles of interstate pipelines, and approximately 2,300 miles of intrastate pipelines. The company was founded in 1882 and is headquartered in Houston, Texas.